Mon. 17 Jun 2024, 9:07am ET
Benzinga
Biotech, News, General
– The Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Trial Without Any Modifications –
– No Safety or Futility Concerns Were Raised Based on the Efficacy and Safety Assessment of All REGAL Patients –
– Interim Analysis Anticipated by Q4 2024 –